High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo

Overview

Journal J Bone Miner Res

Publisher Oxford University Press

Date 2015 Mar 27

PMID 25808845

Citations 12

Authors

Paul J Niziolek

Bryan T MacDonald

Rajendra Kedlaya

Minjie Zhang

Teresita Bellido

Xi He

Matthew L Warman

Alexander G Robling

Affiliations

Soon will be listed here.

Abstract

Certain missense mutations affecting LRP5 cause high bone mass (HBM) in humans. Based on in vitro evidence, HBM LRP5 receptors are thought to exert their effects by providing resistance to binding/inhibition of secreted LRP5 inhibitors such as sclerostin (SOST) and Dickkopf homolog-1 (DKK1). We previously reported the creation of two Lrp5 HBM knock-in mouse models, in which the human p.A214V or p.G171V missense mutations were knocked into the endogenous Lrp5 locus. To determine whether HBM knock-in mice are resistant to SOST- or DKK1-induced osteopenia, we bred Lrp5 HBM mice with transgenic mice that overexpress human SOST in osteocytes ((8kb) Dmp1-SOST) or mouse DKK1 in osteoblasts and osteocytes ((2.3kb) Col1a1-Dkk1). We observed that the (8kb) Dmp1-SOST transgene significantly lowered whole-body bone mineral density (BMD), bone mineral content (BMC), femoral and vertebral trabecular bone volume fraction (BV/TV), and periosteal bone-formation rate (BFR) in wild-type mice but not in mice with Lrp5 p.G171V and p.A214V alleles. The (2.3kb) Col1a1-Dkk1 transgene significantly lowered whole-body BMD, BMC, and vertebral BV/TV in wild-type mice and affected p.A214V mice more than p.G171V mice. These in vivo data support in vitro studies regarding the mechanism of HBM-causing mutations, and imply that HBM LRP5 receptors differ in their relative sensitivity to inhibition by SOST and DKK1.

Citing Articles

LRP5 promotes adipose progenitor cell fitness and adipocyte insulin sensitivity.

Loh N, Vasan S, Rosoff D, Roberts E, van Dam A, Verma M Commun Med (Lond). 2025; 5(1):51.

PMID: 40000740 PMC: 11862225. DOI: 10.1038/s43856-025-00774-1.

Male Lrp5A214V mice maintain high bone mass during dietary calcium restriction by altering the vitamin D endocrine system.

Ozgurel S, Reyes Fernandez P, Chanpaisaeng K, Fleet J J Bone Miner Res. 2024; 39(3):315-325.

PMID: 38477773 PMC: 11240165. DOI: 10.1093/jbmr/zjae011.

The LRP5 high-bone-mass mutation causes alveolar bone accrual with minor craniofacial alteration.

Turkkahraman H, Flanagan S, Zhu T, Bellido T, Yuan X J Periodontal Res. 2023; 58(4):723-732.

PMID: 37128744 PMC: 10330384. DOI: 10.1111/jre.13130.

loss in mesenchymal progenitors causes Job syndrome-like skeletal defects by reducing Wnt/β-catenin signaling.

Yadav P, Feng S, Cong Q, Kim H, Liu Y, Yang Y Proc Natl Acad Sci U S A. 2021; 118(26).

PMID: 34172578 PMC: 8256036. DOI: 10.1073/pnas.2020100118.

Gain-of-Function Lrp5 Mutation Improves Bone Mass and Strength and Delays Hyperglycemia in a Mouse Model of Insulin-Deficient Diabetes.

Leanza G, Fontana F, Lee S, Remedi M, Schott C, Ferron M J Bone Miner Res. 2021; 36(7):1403-1415.

PMID: 33831261 PMC: 8360087. DOI: 10.1002/jbmr.4303.

References

Riddle R, Diegel C, Leslie J, Van Koevering K, Faugere M, Clemens T . Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition. PLoS One. 2013; 8(5):e63323. PMC: 3651091. DOI: 10.1371/journal.pone.0063323. View

Tu X, Rhee Y, Condon K, Bivi N, Allen M, Dwyer D . Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 2011; 50(1):209-17. PMC: 3246572. DOI: 10.1016/j.bone.2011.10.025. View

Goel S, Chin E, Fakhraldeen S, Berry S, Beebe D, Alexander C . Both LRP5 and LRP6 receptors are required to respond to physiological Wnt ligands in mammary epithelial cells and fibroblasts. J Biol Chem. 2012; 287(20):16454-66. PMC: 3351289. DOI: 10.1074/jbc.M112.362137. View

Bao J, Zheng J, Wu D . The structural basis of DKK-mediated inhibition of Wnt/LRP signaling. Sci Signal. 2012; 5(224):pe22. PMC: 3465688. DOI: 10.1126/scisignal.2003028. View

Baron R, Kneissel M . WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013; 19(2):179-92. DOI: 10.1038/nm.3074. View

van Dinther M, Zhang J, Weidauer S, Boschert V, Muth E, Knappik A . Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling. PLoS One. 2013; 8(4):e62295. PMC: 3639248. DOI: 10.1371/journal.pone.0062295. View

Bhat B, Allen K, Liu W, Graham J, Morales A, Anisowicz A . Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling. Gene. 2007; 391(1-2):103-12. DOI: 10.1016/j.gene.2006.12.014. View

Modder U, Clowes J, Hoey K, Peterson J, McCready L, Oursler M . Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2010; 26(1):27-34. PMC: 3132405. DOI: 10.1002/jbmr.128. View

Ai M, Heeger S, Bartels C, Schelling D . Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am J Hum Genet. 2005; 77(5):741-53. PMC: 1271384. DOI: 10.1086/497706. View

10.

Sawakami K, Robling A, Ai M, Pitner N, Liu D, Warden S . The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem. 2006; 281(33):23698-711. DOI: 10.1074/jbc.M601000200. View

11.

Li J, Sarosi I, Cattley R, Pretorius J, Asuncion F, Grisanti M . Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006; 39(4):754-66. DOI: 10.1016/j.bone.2006.03.017. View

12.

Ellies D, Viviano B, McCarthy J, Rey J, Itasaki N, Saunders S . Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res. 2006; 21(11):1738-49. DOI: 10.1359/jbmr.060810. View

13.

Semenov M, He X . LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem. 2006; 281(50):38276-84. DOI: 10.1074/jbc.M609509200. View

14.

Mani A, Radhakrishnan J, Wang H, Mani A, Mani M, Nelson-Williams C . LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science. 2007; 315(5816):1278-82. PMC: 2945222. DOI: 10.1126/science.1136370. View

15.

Mao J, Wang J, Liu B, Pan W, Farr 3rd G, Flynn C . Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell. 2001; 7(4):801-9. DOI: 10.1016/s1097-2765(01)00224-6. View

16.

Gong Y, Slee R, Fukai N, Rawadi G, Roman-Roman S, Reginato A . LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001; 107(4):513-23. DOI: 10.1016/s0092-8674(01)00571-2. View

17.

Boyden L, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick M . High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002; 346(20):1513-21. DOI: 10.1056/NEJMoa013444. View

18.

Hsieh J, Lee L, Zhang L, Wefer S, Brown K, DeRossi C . Mesd encodes an LRP5/6 chaperone essential for specification of mouse embryonic polarity. Cell. 2003; 112(3):355-67. DOI: 10.1016/s0092-8674(03)00045-x. View

19.

Zhang Y, Wang Y, Li X, Zhang J, Mao J, Li Z . The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd. Mol Cell Biol. 2004; 24(11):4677-84. PMC: 416395. DOI: 10.1128/MCB.24.11.4677-4684.2004. View

20.

Kokubu C, Heinzmann U, Kokubu T, Sakai N, Kubota T, Kawai M . Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis. Development. 2004; 131(21):5469-80. DOI: 10.1242/dev.01405. View